Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Spero Therapeutics, Inc. - Common Stock
(NQ:
SPRO
)
2.330
+0.060 (+2.64%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Spero Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Spero Therapeutics Inc (NASDAQ:SPRO) Posts Q3 Revenue and EPS Beat
↗
November 13, 2025
Spero Therapeutics (SPRO) smashed Q3 2025 earnings, with revenue of $5.44M beating $0 estimates and a narrower EPS loss of -$0.13.
Via
Chartmill
Earnings Scheduled For November 13, 2025
↗
November 13, 2025
Via
Benzinga
Insights Ahead: Spero Therapeutics's Quarterly Earnings
↗
November 12, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
August 12, 2025
Via
Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
↗
August 12, 2025
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
Earnings Outlook For Spero Therapeutics
↗
August 11, 2025
Via
Benzinga
An Overview of Spero Therapeutics's Earnings
↗
May 12, 2025
Via
Benzinga
A Glimpse of Spero Therapeutics's Earnings Potential
↗
March 26, 2025
Via
Benzinga
SPERO THERAPEUTICS INC (NASDAQ:SPRO) Reports Mixed Q2 2025 Results with Revenue Beat but Stock Decline
↗
August 12, 2025
SPERO Therapeutics (SPRO) reported Q2 2025 results with $14.19M revenue, beating estimates, but shares fell 6.8%. Phase 3 trial for tebipenem HBr halted early for efficacy.
Via
Chartmill
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
↗
June 09, 2025
Via
Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
↗
May 31, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
May 30, 2025
Via
Benzinga
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts
↗
January 30, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Spero Therapeutics
↗
December 20, 2024
Via
Benzinga
Spero Therapeutics's Earnings Outlook
↗
November 13, 2024
Via
Benzinga
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Unusual volume stocks in Friday's session
↗
May 30, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
May 29, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
May 28, 2025
Via
Benzinga
These stocks are making the most noise in today's session.
↗
May 28, 2025
Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
May 28, 2025
Via
Benzinga
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast
↗
May 28, 2025
Via
Benzinga
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
↗
May 28, 2025
GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.
Via
Benzinga
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings
↗
May 28, 2025
Via
Benzinga
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled
↗
May 28, 2025
The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 28, 2025
Via
Benzinga
Earnings Scheduled For May 13, 2025
↗
May 13, 2025
Via
Benzinga
Earnings Scheduled For March 27, 2025
↗
March 27, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 30, 2024
Via
Benzinga
Earnings Scheduled For November 14, 2024
↗
November 14, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
